<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626079</url>
  </required_header>
  <id_info>
    <org_study_id>11-512</org_study_id>
    <nct_id>NCT01626079</nct_id>
  </id_info>
  <brief_title>Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)</brief_title>
  <acronym>COAPT</acronym>
  <official_title>A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evalve</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Evalve</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
      for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial is to confirm
      the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe
      or severe functional mitral regurgitation (FMR) in Symptomatic Heart Failure Subjects who are
      treated per standard of care and who have been determined by the site's local heart team as
      not appropriate for mitral valve surgery. This randomized controlled trial will provide the
      opportunity to strengthen or add labeling claims regarding safety and clinical benefits of
      the MitraClip System for symptomatic heart failure patients with moderate-to-severe or severe
      functional mitral regurgitation.

      Approximately 610 subjects will be randomized at up to 100 investigational sites with
      approximately 305 subjects targeted to receive the study device.

      As part of the COAPT trial, a subset of patients will be registered in the cardiopulmonary
      exercise (CPX) sub-study. The objective of this sub-study is to evaluate the exercise
      responses in a sub-cohort of COAPT subjects who receive MitraClip device (Device group)
      compared to the Control group who do not receive MitraClip device. (Note: the CPX Sub-study
      subjects will contribute to the analyses of the COAPT primary and secondary endpoints)

      As an extension of the COAPT RCT trial, COAPT CAS study will be conducted after COAPT
      enrollment is complete under the same investigational device exemption (IDE(G120024)). The
      objective of this study is to evaluate the MitraClip® NT System for the treatment of
      clinically significant functional mitral regurgitation (FMR) in symptomatic heart failure
      subjects who are treated per standard of care and who have been determined by the site's
      local heart team as not appropriate for mitral valve surgery. The anticipated study Primary
      Completion date is July 2020 and the Study Completion Date is July 2024.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, parallel-controlled, multicenter clinical evaluation of the
      MitraClip device for the treatment of clinically significant functional mitral regurgitation
      in symptomatic heart failure subjects who are treated per standard of care and who have been
      determined by the site's local heart team as not appropriate for mitral valve surgery.
      Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (Device group) or
      to no MitraClip device (Control group).

      As part of the COAPT trial, a subset of patients (at least 50 up to 100 in total) will be
      registered in the CPX Sub-study, which is designed as a prospective, randomized (1:1 ratio to
      the MitraClip or no MitraClip device), parallel-controlled, multicenter study registering
      approximately 50-100 subjects in up to 50 qualified US sites from the COAPT trial. Subjects
      registered and randomized in the CPX Sub-study will contribute to the total enrollment
      approximately of 610 subjects in the COAPT trial. Roll-in subjects will not participate in
      the CPX Sub-study.

      The COAPT CAS study is designed as a prospective, multicenter, single arm, continued access
      registry study. A maximum of 800 subjects (anticipated) will be registered from up to 75
      sites in the United States. The enrollment will end once pre-market approval (PMA) of the
      proposed expanded indication of MitraClip System is obtained. Active follow-up of patients
      will be performed through 12 months with scheduled visits at 30 days and 12 months. The
      national Trans catheter Valve Therapy Registry (TVT Registry) will be used for data
      collection through 12 months. Annual follow-up data from 2 years through year 5 post-implant
      will be obtained by linkage to the Centers for Medicare and Medicaid Services (CMS) Claims
      database.

      COAPT CAS data may be used to support the PMA application of the labeling claims for the
      treatment of moderate to severe or severe FMR in symptomatic heart failure subjects.

      This single arm registry will provide valuable new information regarding use of the
      MitraClip® NT System under more &quot;real world&quot; conditions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary safety endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, and any device related complications requiring non-elective cardiovascular surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary effectiveness endpoint</measure>
    <time_frame>24 months</time_frame>
    <description>To support the primary effectiveness endpoint analysis, clinical sites and all randomized subjects (or their identified contacts) will be contacted to determine each subject's survival status and date(s) of last known heart failure hospitalizations. This data sweep of death and heart failure hospitalizations will be conducted when the last randomized subject has passed the upper limit of the window for the 12-month follow-up period (i.e., 395 days after enrollment). The sweep contact is not needed for subjects who had a follow-up visit within 30 days of the sweep date, or for subjects who already completed their 24-month follow-up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transient ischemic attack (TIA) (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transient ischemic attack (TIA) (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal complication with requirement for dialysis (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal complication with requirement for dialysis (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major vascular complications (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major vascular complications (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major and/or life threatening bleeding (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major and/or life threatening bleeding (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitral Regurgitation (MR) severity (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mitral Regurgitation (MR) severity (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Six Minute Walk Test (6MWT distance or 6MWD) (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Six Minute Walk Test (6MWT distance or 6MWD) (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life (QOL) (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
    <description>Quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life (QOL) (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A composite of all-cause death, stroke, MI, or non-elective cardiovascular surgery for device related complications in the Device group</measure>
    <time_frame>30 days post-procedure in the Device group</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation severity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in distance walked on the 6 Minute Walk Test (6MWT distance or 6MWD)</measure>
    <time_frame>12 months over baseline</time_frame>
    <description>The 6MWT is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QoL) as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>12 months over baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume (LVEDV)</measure>
    <time_frame>12 months over baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class I/II</measure>
    <time_frame>12 months</time_frame>
    <description>NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA CLASS)
Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent hospitalizations - all cause</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hierarchical composite of death and recurrent HF hospitalization hospitalization (analyzed when the last subject completes 12 months of follow-up)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and primary cause of death (COAPT CAS study analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction (MI) (COAPT CAS study analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS study analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) hospitalization (COAPT CAS study analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>Within and after 30 days of the procedure</time_frame>
    <description>Device or procedure-related adverse events are defined as adverse events that are adjudicated by the Clinical Events Committee as possibly, probably or definitely device and/or procedure-related, regardless of the temporal relationship to the MitraClip procedure. Device or procedure-related adverse events will be broken down into those that occur within 30 days of the procedure and those that occur after 30 days of the procedure. Examples of device-related adverse events are: myocardial perforation, Single Leaflet Device Attachment, embolization of the MitraClip device or MitraClip System components, iatrogenic atrial septal defect, mitral valve stenosis, need for mitral valve replacement instead of repair due at least in part to the MitraClip procedure or the presence of the MitraClip device.</description>
  </other_outcome>
  <other_outcome>
    <measure>Implant Rate</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the rate of successful delivery and deployment of the MitraClip device(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter</description>
  </other_outcome>
  <other_outcome>
    <measure>Device Procedure Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time elapsed from the first of any of the following: intravascular catheter placement, anesthesia or sedation, or transesophageal echocardiogram (TEE), to the removal of the last catheter and TEE</description>
  </other_outcome>
  <other_outcome>
    <measure>Device Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy duration</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the duration of exposure to fluoroscopy during the MitraClip procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the mitral valve (present or absent)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the components of the primary safety composite</measure>
    <time_frame>12 months in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the components of the primary safety composite</measure>
    <time_frame>24 months in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the components of the primary safety composite</measure>
    <time_frame>3 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the components of the primary safety composite</measure>
    <time_frame>4 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the components of the primary safety composite</measure>
    <time_frame>5 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the primary safety composite</measure>
    <time_frame>24 months in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the primary safety composite</measure>
    <time_frame>3 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the primary safety composite</measure>
    <time_frame>4 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the primary safety composite</measure>
    <time_frame>5 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from all-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from all-cause mortality</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from all-cause mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from all-cause mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from all-cause mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from cardiovascular mortality</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from cardiovascular mortality</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from cardiovascular mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from cardiovascular mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from cardiovascular mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first cardiovascular hospitalization</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first cardiovascular hospitalization</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first cardiovascular hospitalization</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first cardiovascular hospitalization</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first cardiovascular hospitalization</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization or all-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization or all-cause mortality</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization or all-cause mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization or all-cause mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier freedom from the first HF related hospitalization or all-cause mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six-Minute Walk Test Distance (6MWD)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD from baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD from baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD from baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD from baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ) QoL scores</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL scores</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL scores</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL scores</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL scores</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL scores from baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL scores from baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL scores from baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL scores from baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL scores</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL scores</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL scores</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL scores</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL scores</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL scores from baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL scores from baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL scores from baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL scores from baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve surgery (including type of surgery), new use of CRT, new use of single or dual chamber pacemaker, permanent LVAD implant, heart transplant, additional MitraClip device intervention in Device group</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>De novo MitraClip device intervention in Control group</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for 6MWD</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for 6MWD</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for LVEDV Index</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for LVEDV Index</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for LVEDV Index</measure>
    <time_frame>3 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for LVEDV Index</measure>
    <time_frame>4 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for LVEDV Index</measure>
    <time_frame>5 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for QoL (KCCQ)</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder analysis for QoL (KCCQ)</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Each subscale for QoL (KCCQ)</measure>
    <time_frame>12 months</time_frame>
    <description>difference in means between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Each subscale for QoL (KCCQ)</measure>
    <time_frame>24 months</time_frame>
    <description>difference in means between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of index hospitalization for MitraClip procedure (Device group)</measure>
    <time_frame>Before MitraClip procedure on day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospitalizations and reason for hospitalization (i.e. heart failure, cardiovascular, non-cardiovascular)</measure>
    <time_frame>12 months</time_frame>
    <description>in each of the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospitalizations and reason for hospitalization (i.e. heart failure, cardiovascular, non-cardiovascular)</measure>
    <time_frame>24 months</time_frame>
    <description>in each of the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>From the time of randomization to 12 months</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>From the time of randomization to 24 months</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>From the time of randomization to 3 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>From the time of randomization to 4 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days alive and out of hospital</measure>
    <time_frame>From the time of randomization to 5 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days hospitalized from the &quot;Treatment&quot; visit</measure>
    <time_frame>12 months</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days hospitalized from the &quot;Treatment&quot; visit</measure>
    <time_frame>24 months</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days hospitalized from the &quot;Treatment&quot; visit</measure>
    <time_frame>3 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days hospitalized from the &quot;Treatment&quot; visit</measure>
    <time_frame>4 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days hospitalized from the &quot;Treatment&quot; visit</measure>
    <time_frame>5 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of alive time in hospital</measure>
    <time_frame>12 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of alive time in hospital</measure>
    <time_frame>24 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of alive time in hospital</measure>
    <time_frame>3 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of alive time in hospital</measure>
    <time_frame>4 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of alive time in hospital</measure>
    <time_frame>5 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects living in the baseline location</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects living in the baseline location</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects living in the baseline location</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects living in the baseline location</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects living in the baseline location</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve replacement rates</measure>
    <time_frame>12 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve replacement rates</measure>
    <time_frame>24 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve replacement rates</measure>
    <time_frame>3 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve replacement rates</measure>
    <time_frame>4 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral valve replacement rates</measure>
    <time_frame>5 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>New onset of permanent atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New onset of permanent atrial fibrillation</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New onset of permanent atrial fibrillation</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New onset of permanent atrial fibrillation</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New onset of permanent atrial fibrillation</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral stenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral stenosis</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral stenosis</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral stenosis</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral stenosis</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant atrial septal defect (ASD) that requires intervention</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant atrial septal defect (ASD) that requires intervention</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant atrial septal defect (ASD) that requires intervention</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant atrial septal defect (ASD) that requires intervention</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically significant atrial septal defect (ASD) that requires intervention</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device-related complications in Device group subjects and Control group subjects who undergo the MitraClip procedure</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Brain Natriuretic Peptide (BNP) or N-terminal prohormone of Brain Natriuretic Peptide (NT-proBNP levels)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BNP or NT-proBNP levels</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BNP or NT-proBNP levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>Baseline</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>30 days</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>6 months</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>12 months</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research Consortium (BARC) definition</description>
  </other_outcome>
  <other_outcome>
    <measure>Prolonged ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as pulmonary insufficiency requiring ventilatory support for greater than 48 hours post-catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of Guideline Directed Medical Therapy (GDMT)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average dosages of GDMT</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT and GDMT dosage from baseline</measure>
    <time_frame>Between baseline and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number and reasons for any changes in GDMT from baseline that result in a greater than 100% increase or greater than 50% decrease in dose</measure>
    <time_frame>Between baseline and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary exercise (CPX) testing</measure>
    <time_frame>Baseline</time_frame>
    <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a
parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary exercise (CPX) testing</measure>
    <time_frame>12 months</time_frame>
    <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary exercise (CPX) testing: mean changes in peak VO2</measure>
    <time_frame>Between baseline and 12 months</time_frame>
    <description>Mean changes in peak VO2 (ml/kg/min) will be summarized at 12 months from baseline for the subset of patients who complete a CPX test at baseline and 12 months. A comparison of change from baseline between Device and Control groups will be presented.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic Data</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">610</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MitraClip System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous mitral valve repair using MitraClip System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip System</intervention_name>
    <description>Percutaneous mitral valve repair using MitraClip System</description>
    <arm_group_label>MitraClip System</arm_group_label>
    <other_name>MitraClip device</other_name>
    <other_name>MitraClip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic functional MR (≥3+) due to cardiomyopathy of either ischemic or
             non-ischemic etiology determined by assessment of a qualifying transthoracic
             echocardiogram (TTE) obtained within 90 days and transesophageal echocardiogram (TEE)
             obtained within 180 days prior to subject registration, with MR severity based
             principally on the TTE study, confirmed by the Echocardiography Core Lab (ECL). The
             ECL may request a transesophageal echocardiogram (TEE) to confirm MR etiology.

             Note: Functional MR requires the presence of global or regional left ventricular wall
             motion abnormalities, which are believed to be the primary cause of the MR. If a flail
             leaflet or other evidence of degenerative MR is present, the subject is not eligible
             even if global or regional left ventricular systolic dysfunction is present.

             Note: Qualifying TTE must be obtained after the subject has been stabilized on optimal
             therapy including Guideline Directed Medical Therapy (GDMT) and at least 30 days
             after:

               1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

               2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
                  or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
                  biventricular pacing (from &lt;92% to ≥92%)

          2. In the judgment of the HF specialist investigator at the site, the subject has been
             adequately treated per applicable standards, including for coronary artery disease,
             left ventricular dysfunction, mitral regurgitation and heart failure (e.g., with
             cardiac resynchronization therapy, revascularization, and/or GDMT). The Eligibility
             Committee must also concur that the subject has been adequately treated.

          3. New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.

          4. The Local Site Heart Team (CT surgeon and HF specialist investigators) and the Central
             Eligibility Committee concur that surgery will not be offered as a treatment option
             and that medical therapy is the intended therapy for the subject, even if the subject
             is randomized to the Control group.

          5. The subject has had at least one hospitalization for heart failure in the 12 months
             prior to subject registration and/or a corrected brain natriuretic peptide (BNP) ≥300
             pg/ml or corrected n-Terminal pro- brain natriuretic peptide NT-proBNP ≥1500 pg/ml
             measured within 90 days prior to subject registration (&quot;corrected&quot; refers to a 4%
             reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg/m2 in BMI above a
             reference BMI of 20 kg/m2).

             Note: BNP or NT-proBNP must be obtained after the subject has been stabilized on GDMT
             and at least 30 days after:

               1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

               2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
                  or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
                  biventricular pacing (from &lt;92% to ≥92%).

          6. Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50% within 90 days prior to
             subject registration, assessed by the site using any one of the following methods:
             echocardiography, contrast left ventriculography, gated blood pool scan or cardiac
             magnetic resonance imaging (MRI).

             Note: The method must provide a quantitative readout (not a visual assessment).

          7. The primary regurgitant jet is non-commissural, and in the opinion of the MitraClip
             implanting investigator can be successfully be treated by the MitraClip. If a
             secondary jet exists, it must be considered clinically insignificant.

          8. Creatine Kinase-MB (CK-MB) obtained within prior 14 days &lt; local laboratory Upper
             Limit of Normal (ULN).

          9. Transseptal catheterization and femoral vein access is determined to be feasible by
             the MitraClip implanting investigator.

         10. Age 18 years or older.

         11. The subject or the subject's legal representative understands and agrees that should
             he/she be assigned to the Control group, he/she will be treated with medical therapy
             and conservative management without surgery and without the MitraClip, either
             domestically or abroad. If the subject would actively contemplate surgery and/or
             MitraClip if randomized to Control, he/she should not be registered in this trial.

         12. The subject or the subject's legal representative has been informed of the nature of
             the trial and agrees to its provisions, including the possibility of randomization to
             the Control group and returning for all required post-procedure follow-up visits, and
             has provided written informed consent.

         13. Left Ventricular End Systolic Dimension (LVESD) is ≤ 70 mm assessed by site based on a
             transthoracic echocardiographic (TTE) obtained within 90 days prior to subject
             registration.

        For the CPX Sub-study: Subjects have to meet the COAPT study eligibility criteria to be
        registered in the CPX Sub-study.

        COAPT CAS study Inclusion Criteria:

        1. Subjects must meet all of the above COAPT RCT inclusion criteria, and must have national
        Medicare coverage by the Centers for Medicare and Medicaid Services (CMS).

        Exclusion Criteria:

          1. Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy
             or chronic outpatient oral steroid use.

          2. Untreated clinically significant coronary artery disease requiring revascularization.

          3. Coronary artery bypass grafting (CABG) within 30 days prior to subject registration.

          4. Percutaneous coronary intervention within 30 days prior to subject registration.

          5. Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject
             registration.

          6. Tricuspid valve disease requiring surgery or transcatheter intervention.

          7. Aortic valve disease requiring surgery.

          8. Cerebrovascular accident within 30 days prior to subject registration.

          9. Severe symptomatic carotid stenosis (&gt; 70% by ultrasound).

         10. Carotid surgery or stenting within 30 days prior to subject registration.

         11. American College of Cardiology /American Heart Association (ACC/AHA) Stage D heart
             failure.

         12. Presence of any of the following:

               -  Estimated pulmonary artery systolic pressure (PASP) &gt; 70 mm Hg assessed by site
                  based on echocardiography or right heart catheterization, unless active
                  vasodilator therapy in the cath lab is able to reduce the pulmonary vascular
                  resistance (PVR) to &lt; 3 Wood Units or between 3 and 4.5 Wood Units with v wave
                  less than twice the mean of the pulmonary capillary wedge pressure

               -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive
                  pericarditis, or any other structural heart disease causing heart failure other
                  than dilated cardiomyopathy of either ischemic or non ischemic etiology

               -  Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)

               -  Hemodynamic instability requiring inotropic support or mechanical heart
                  assistance.

         13. Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction as assessed by site.

         14. Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization
             Therapy with cardioverter-defibrillator (CRT-D) within the last 30days prior to
             subject registration.

         15. Mitral valve orifice area &lt; 4.0 cm2 assessed by site based on a transthoracic
             echocardiogram (TTE) within 90 days prior to subject registration.

         16. Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip
             positioning on the leaflets or sufficient reduction in MR by the MitraClip. This
             evaluation is based on transesophageal echocardiogram (TEE) evaluation of the mitral
             valve within 180 days prior to subject registration and includes:

               -  Insufficient mobile leaflet available for grasping with the MitraClip device

               -  Evidence of calcification in the grasping area

               -  Presence of a significant cleft in the grasping area

               -  Lack of both primary and secondary chordal support in the grasping area

               -  Leaflet mobility length &lt; 1 cm

         17. Hemodynamic instability defined as systolic pressure &lt; 90 mmHg with or without
             afterload reduction, cardiogenic shock or the need for inotropic support or
             intra-aortic balloon pump or other hemodynamic support device.

         18. Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months.

         19. Life expectancy &lt; 12 months due to non-cardiac conditions.

         20. Modified Rankin Scale ≥ 4 disability.

         21. Status 1 heart transplant or prior orthotopic heart transplantation.

         22. Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve,
             or any prior transcatheter mitral valve procedure.

         23. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

         24. Active endocarditis or active rheumatic heart disease or leaflets degenerated from
             rheumatic disease (i.e., noncompliant, perforated).

         25. Active infections requiring current antibiotic therapy.

         26. Subjects in whom transesophageal echocardiography (TEE) is contraindicated or high
             risk.

         27. Known hypersensitivity or contraindication to procedural medications which cannot be
             adequately managed medically.

         28. Pregnant or planning pregnancy within next 12 months.

             Note: Female patients of childbearing age should be instructed to use safe
             contraception (e.g. intrauterine devices, hormonal contraceptives: contraceptive
             pills, implants, transdermal patches hormonal vaginal devices, injections with
             prolonged release.

         29. Currently participating in an investigational drug or another device study that has
             not reached its primary endpoint. Note: Trials requiring extended follow-up for
             products that were investigational, but have since become commercially available, are
             not considered investigational trials.

         30. Subject belongs to a vulnerable population per investigator's judgment or subject has
             any kind of disorder that compromises his/her ability to give written informed consent
             and/or to comply with study procedures.

        For the CPX Sub-study: Subjects who have any contraindications to CPX and are not capable
        of performing CPX per investigator's assessment should not be registered in the CPX
        Sub-study.

        COAPT CAS study Exclusion Criteria:

        1. Subjects must not meet any of the above COAPT RCT exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center / New York-Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William T Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JoAnn Lindenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jami Maccombs</last_name>
    <email>jami.maccombs@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren E Edwards</last_name>
    <email>ledwards@novellaclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saibal Kar, MD</last_name>
      <phone>310-423-3978</phone>
      <email>karsk@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chad Rammohan, MD</last_name>
      <email>rammohc@pamf.org</email>
    </contact>
    <investigator>
      <last_name>Chad Rammohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Rogers, MD</last_name>
      <phone>916-734-3764</phone>
      <email>jason.rogers@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Rogers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Yeung, MD</last_name>
      <email>ayeung@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Yeung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig D Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Brieke, MD</last_name>
      <phone>303-724-2102</phone>
      <email>Andreas.brieke@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Andreas Brieke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Batchelor, MD</last_name>
      <phone>850-216-0120</phone>
      <email>wabat@southern-med.com</email>
    </contact>
    <investigator>
      <last_name>Wayne Batchelor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark J Ricciardi, MD</last_name>
      <phone>312-695-4965</phone>
      <email>mricciar@nmff.org</email>
    </contact>
    <investigator>
      <last_name>Patrick McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clifford Kavinsky, MD</last_name>
      <email>clifford_j_kavinsky@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Clifford Kavinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Feldman, MD</last_name>
      <email>tfeldman@tfeldman.org</email>
    </contact>
    <investigator>
      <last_name>Ted Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hermiller, MD</last_name>
      <email>jhermill@thecaregroup.com</email>
    </contact>
    <investigator>
      <last_name>James Hermiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hosp Authority</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital - Lexington, KY</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vesley, MD</last_name>
      <phone>410-328-5842</phone>
      <email>mvesely@medicine.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>James Gammie, MD</last_name>
      <email>jsgammiemd@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Vesley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Gammie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Palacios, MD</last_name>
      <phone>617-726-8424</phone>
      <email>ipalacios@partners.org</email>
    </contact>
    <investigator>
      <last_name>Igor Palacios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Garrett Stewart, MD</last_name>
      <phone>617-525-9573</phone>
      <email>GCSTEWART@PARTNERS.ORG</email>
    </contact>
    <investigator>
      <last_name>Garrett Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6796</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Goessl, MD</last_name>
      <phone>612-863-3900</phone>
      <email>mario.goessl@allina.com</email>
    </contact>
    <investigator>
      <last_name>Mario Goessl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladwin Das, MD</last_name>
      <email>dasxx007@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Gladwin Das, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation for Med Edu And Research</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Reeder, MD</last_name>
      <phone>507-255-0876</phone>
      <email>reeder.guy@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Guy Reeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth Huber, MD</last_name>
      <email>khuber@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Huber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lasala, MD, PhD</last_name>
      <phone>314-362-3729</phone>
      <email>jlasala@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>John Lasala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kipperman, MD</last_name>
      <phone>973-467-0005</phone>
      <email>rkipperman@okheart.com</email>
    </contact>
    <investigator>
      <last_name>Robert Kipperman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cezar Staniloae, MD</last_name>
      <email>cezar.staniloae@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Cezar Staniloae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susheel Kodali, MD</last_name>
      <phone>212-342-0444</phone>
      <email>skodali@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Susheel Kodali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew D Berke, MD</last_name>
      <email>aberke.md@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andrew D Berke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Rinaldi, MD</last_name>
      <phone>704-355-4794</phone>
      <email>Michael.Rinaldi@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Michael J Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Wang, MD</last_name>
      <phone>919-681-6197</phone>
      <email>a.wang@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Sarembock, MD</last_name>
      <phone>513-585-1777</phone>
      <email>sarembock@ohioheart.org</email>
    </contact>
    <investigator>
      <last_name>Ian Sarembock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Kapadia, MD</last_name>
      <phone>216-444-6697</phone>
      <email>kapadis@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Samir Kapadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Ghani, MD</last_name>
      <phone>405-608-3800</phone>
      <email>mghani@ohkeart.com</email>
    </contact>
    <contact_backup>
      <last_name>John Williams, MD</last_name>
      <email>jwilliams@okheart.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Ghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Korngold, MD</last_name>
      <phone>503-216-0900</phone>
      <email>Ethan.Korngold@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ethan Korngold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saurabh Gupta, MD</last_name>
      <email>guptasa@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Saurabh Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Firas Zahr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of University Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <phone>717-231-8585</phone>
      <email>mmumtaz@pinnaclehealth.org</email>
    </contact>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelio Rodriguez, MD</last_name>
      <phone>615-222-5500</phone>
      <email>evelio.rodriguez@stthomas.org</email>
    </contact>
    <investigator>
      <last_name>Evelio Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Grayburn, MD</last_name>
      <email>paulgr@baylorhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Mack, MD</last_name>
      <phone>214-820-7358</phone>
      <email>michael.mack@baylorhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Grayburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Whisenant, MD</last_name>
      <phone>801-507-4700</phone>
      <email>brian.whisenant@imail.org</email>
    </contact>
    <investigator>
      <last_name>Brian Whisenant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cherry Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Paul's - Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Symptomatic Heart Failure</keyword>
  <keyword>Functional MR</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Cardiopulmonary exercise testing</keyword>
  <keyword>COAPT CAS</keyword>
  <keyword>COAPT Continued Access Study</keyword>
  <keyword>MitraClip NT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

